The Mid-Year Reset

The Setup

Every stock that falls has a story, and the story is usually some version of "the market knows something." Sometimes that is true. A drawdown in a weak business is often the market correctly pricing deterioration. But a drawdown in a strong business is a different animal, because it forces a choice: either the fundamentals are about to break, or the price got ahead of itself and is now resetting to something more reasonable. The first is a falling knife. The second is the closest thing public markets offer to a sale on quality.

So here is the screen. We started with every company the platform rates Strong or Elite on Company Strength with a market cap above $5 billion: 177 names. We kept only the ones flat or down year to date through the July 2 close: 96 names, or 54% of the entire quality universe. Then we filtered hard. Software names came out, no matter how far they had fallen, for reasons regular readers know from The SaaS Reckoning. Gold miners came out because we covered them in last week's edition. Names with known fair-value artifacts came out for data integrity. What survived is five companies with five very different first halves and one shared profile: growing earnings, healthy balance sheets, Bullish platform outlooks, and prices that fell anyway, in every case to within a few percent of the platform's calculated fair value.

That last detail is the point of this list. None of these five screens as a deep bargain, and we will not pretend otherwise. What they screen as is something rarer: high-quality businesses at fair prices. Companies with Financial Health scores between 73 and 90 and Moat scores of 12/15 or better usually trade at premiums to fair value, sometimes large ones. The first half of 2026 compressed those premiums to zero. This article is about what knocked each one down, and what the data says about whether the damage is to the price or the business.

ResMed (RMD)

ResMed (RMD) is the global leader in devices that treat sleep apnea, wrapped around a growing health-software business, and it is the highest-scoring name on this list: an Elite Company Strength of 86, a Financial Health score of 90/100, and a near-perfect Moat of 14/15. It is also down roughly 14% year to date and about a third below its August 2025 high near $294, which makes it the cleanest example of the pattern this list exists to catch.

Because the business did not follow the stock down. Fiscal third-quarter results reported April 30 showed revenue up 11% to $1.43 billion and non-GAAP earnings up 21% to $2.86 per share, both ahead of consensus, with gross margin expanding 290 basis points to 62.8%. What fell was the multiple, and the reasons are all forward-looking fears: GLP-1 weight-loss drugs winning approvals to treat sleep apnea directly, the possibility of Philips re-entering the U.S. device market, and a mid-June Morgan Stanley downgrade that cut the price target to $230 and argued margin expansion is near its ceiling. The stock now trades around 17 times forward earnings, well below its own history and the medtech peer group.

The counterargument comes from ResMed's own data. The company tracks 2.1 million patients holding both GLP-1 and airway-pressure prescriptions, and reports that those patients start device therapy at roughly 11% higher rates and stay on resupply at more than 6% higher rates over three years than device-only patients. The drugs that were supposed to shrink the patient pool are, so far, producing more engaged patients. The market is pricing the fear. The reported numbers keep printing the opposite.

Tradeweb (TW)

Tradeweb (TW) operates the electronic marketplaces where an enormous share of the world's bonds, swaps, and money-market instruments change hands, and its first quarter was the best in company history. Revenue crossed $600 million for the first time, up 21.2% year over year to $617.8 million. Average daily volume hit a record $3.3 trillion, up 31.4%, with quarterly records across U.S. and European government bonds, mortgages, swaps, and fully electronic credit. Adjusted earnings grew 25.6%, the adjusted EBITDA margin reached 55%, and international revenue grew 29% to become 44% of the business.

The stock's response to the best quarter ever: a slow drift lower. Tradeweb sits down about 3% for the year and roughly a third below its 52-week high of $149, because the market spent the first half compressing the multiple rather than questioning the business. The trailing price-to-earnings ratio de-rated below 30, cheap by this company's standards, on a reasonable worry: volumes this strong are partly a product of rate volatility, and calm markets would slow the growth engine. April data showed the shape of that concern, with daily volumes still up 7.7% year over year but average daily revenue trending slightly lower on mix.

The platform rates Tradeweb Elite at 82 with a Growth score of 13/15, and its fair value of $95 sits about 6% below the current price, close enough to earn a Fair Value tag. The structural argument is what the de-rating may be underpricing: the migration of fixed-income trading from phones to screens is a decades-long, one-directional trend, and Tradeweb collects a toll on it in every rate environment. Volatility decides how fast the meter runs. It does not decide whether the meter exists.

Kinsale Capital (KNSL)

Kinsale Capital (KNSL) writes excess and surplus lines insurance, the hard-to-place risks standard carriers will not touch, and does it with a technology-driven cost structure that has made it one of the most profitable underwriters in America. First-quarter net operating earnings grew 38% to $5.11 per diluted share, beating estimates by 9%, and the board raised the dividend for the tenth consecutive year. This is the smallest company on the list and, by long-run growth rate, historically the fastest.

Which is exactly why it is down about 10% this year. The excess and surplus market is softening after a multi-year hard market, and CEO Michael Kehoe now describes conditions plainly as "a competitive market." Revenue growth of 10% is excellent for an insurer and a visible step down from the 30%-plus rates Kinsale compounded at for years. Sell-side firms spent the spring trimming price targets across the property and casualty group, and a short-seller report pushed investors to re-examine Kinsale's reserve history and exposure to large losses. Growth stocks get repriced when growth decelerates, even when the underlying returns stay elite.

The platform's read: Strong at 77, a 12/15 Moat, a 13/15 Growth score, and a fair value of $359 that sits 1% above the current price. That is the single tightest price-to-fair-value fit on this list, and for this particular company it is remarkable. Kinsale spent most of its public life trading at premium multiples that assumed hypergrowth forever. The first half took that assumption out of the price. What remains is a best-in-class underwriter, still growing double digits, still raising its dividend, priced at almost exactly what the models say the business is worth today.

Deckers (DECK)

Deckers (DECK) is the parent of HOKA and UGG, and regular readers have seen this name before: we published a full Investment Thesis on it in May, two days before the company reported results that validated most of it. Fiscal 2026 closed as a record year. Revenue grew 10% to $5.47 billion, earnings per share grew 11% to $7.02, and HOKA posted the largest quarter in its history at $671 million on its way to $2.59 billion for the year, up 16%. The fourth quarter beat earnings estimates by roughly 16%. The company holds $1.9 billion in cash, bought back over $1 billion of stock during the year, and the board added $3.5 billion to the repurchase authorization.

And yet the stock sits slightly red for the year, down about 2%, because the market is focused on the guide rather than the record. Fiscal 2027 guidance calls for revenue of $5.86 to $5.91 billion and an operating margin near 21.5%, a step down from 23.1%, as freight, input costs, and tariffs bite; tariffs alone cost the company 80 basis points of gross margin last year. Add a guided one-quarter HOKA deceleration on wholesale timing, and a nervous consumer backdrop, and the market decided a record year was worth roughly nothing.

The platform disagrees with the shrug. It rates Deckers Strong at 75 with a Financial Health score of 89/100, second only to ResMed on this list, and calculates fair value at $110, about 5% above the current price. The company guided to low-double-digit EPS growth through 2030. A fortress balance sheet, two growing global brands, a shrinking share count, and a fair-value price is not a common combination in consumer discretionary. The first half of 2026 produced it anyway.

Copart (CPRT)

Copart (CPRT) runs the dominant online auction network for totaled and salvage vehicles, a business with a land-and-logistics moat that took five decades to build, and it is the deepest drawdown on this list: down about 21% this year, down roughly 46% over twelve months, and touching a 52-week low near $29 within the past week. Unlike the other four, Copart's numbers did wobble. Fiscal second-quarter revenue fell 3.6% and earnings missed, knocking the stock down 11% in a day. The cause is specific: U.S. insurance auction volumes declined as rising premiums pushed consumers to drop or reduce coverage. Industry data cited by management showed insured car-years falling 4% even as vehicles on the road grew 1.4%. Fewer insured cars means fewer insurer-consigned wrecks to auction.

The bull-bear fight is over one word: cyclical. Management argues households eventually restore the coverage they need, and the most recent quarter supports the stabilization case. Fiscal third-quarter revenue returned to growth, up 2.1% to $1.24 billion and ahead of estimates, earnings beat, U.S. insurance unit declines narrowed to 4.2% from high single digits, average selling prices for insurance consignors set records, and international revenue grew 14.1%. Then, in late June, a surprise CEO transition took another 8% out of the stock in a week, a sentiment blow layered onto an already washed-out chart.

What has not moved is the structure underneath. Total-loss frequency, the share of damaged cars insurers write off rather than repair, has climbed from 15.6% in 2015 to 24.2%, a decade-long ratchet driven by ever more expensive vehicle repair. Copart holds $6.4 billion in liquidity with zero debt and grew free cash flow 58% through the first half of its fiscal year. The platform rates it Strong at 73 with a Financial Health of 85/100 and a 12/15 Moat, and its $32 fair value sits 8% above the price, the largest discount of the five. At roughly 17 times trailing earnings, against a history of trading near twice that, the market has priced the volume slump as permanent. The data so far reads more like a cycle.

What the Wealth Engine Scores Say

Here is the platform's systematic read on all five, current as of this week. Notice what is missing: not one of these names carries an Undervalued tag.

Read the pattern honestly. Two Elite ratings, three Strong, every outlook Bullish, and five Fair Value tags in a row. The platform is not calling any of these stocks cheap. ResMed and Tradeweb still trade modestly above their calculated fair values; Kinsale, Deckers, and Copart sit modestly below. If you came looking for deep-discount bargains, this is not that list, and pretending otherwise would break the entire premise of this publication.

These scores are systematic. They evaluate companies on reported financials, balance sheet quality, moat characteristics, and valuation models including discounted cash flow, peer comparison, and earnings power. They measure what a company is today, not what it might become, and by design they carry no memory of where a stock used to trade and no opinion about where it is going.

The editorial argument sits in exactly that blind spot. Businesses with health scores of 73 to 90 and moats of 12/15 or better almost never trade at fair value; the market habitually pays a premium for proven quality, which is why lists like this are usually impossible to build. The first half of 2026 built it for us. Whether that compression is an opportunity or an omen is the judgment the scores cannot make. The platform says the current fundamentals are solid and the prices are reasonable. The article argues that for companies of this caliber, reasonable is the anomaly. Both readings are real data. Research any of these names on the platform and decide which signal matters more for your situation.

What Didn't Make the List

The single largest group of quality laggards was software, and the drawdowns there are not subtle: Intuit down 56% year to date, Adobe down 34%, PTC down 27%, Microsoft down 17%, all while still carrying Strong or Elite ratings on trailing financials. They are excluded on standing editorial policy. This publication laid out in The SaaS Reckoning why AI structurally threatens the seat-based software model, and a screen built on backward-looking scores cannot see that threat coming. The irony is not lost on us that our own laggard screen is now full of the stocks that thesis warned about. That is what a thesis playing out looks like.

Gold miners were the second-largest group. Barrick, Newmont, Kinross, and Gold Fields all qualified on the raw numbers after the metal's recent pullback, and all were set aside for a simpler reason: we covered the sector in last week's edition and have nothing new to add seven days later.

Two exclusions were about data integrity. Hartford and Ameriprise both screened as Strong laggards with Deep Value tags and enormous calculated upside, a pattern we have learned to distrust: float-heavy insurance balance sheets routinely break the fair-value models, producing discounts that are artifacts rather than opportunities. And two names that initially screened as down for the year, KLA and Mueller Industries, turned out to be up once we corrected for stock splits the raw price series had not adjusted for. When a number looks wrong, we check it before we print it. Both came off the list.

What Could Go Wrong

The honest name for the risk in this list is the quality trap. Every stock here is down because a real, live bear case exists, and buying a laggard means taking the other side of five separate arguments at once. ResMed's decline prices GLP-1 drugs eventually diverting new patients from devices and Philips returning to the U.S. market; the company's adherence data is encouraging, but the drug approvals are recent and the long-run patient math is genuinely unsettled. Tradeweb's de-rating prices volume normalization, and that concern is arithmetic, not paranoia: record volumes were partly a gift from rate volatility, and a calm second half would slow the growth that justifies even the compressed multiple.

Kinsale carries cycle risk on top of growth risk. If excess and surplus pricing keeps softening, this year's 38% earnings growth is a peak, not a base, and the reserve questions the short report raised are the kind that take years, not quarters, to fully resolve. Deckers guided its own operating margin down to roughly 21.5%, tariffs and freight are live headwinds, and HOKA now fights On, Nike, and a crowded running market for every point of growth; a consumer downturn would hit all of it at once. Copart carries the biggest single question on the list: if households dropping insurance coverage is structural rather than cyclical, auction volumes do not come back, and the narrowing unit declines of the latest quarter turn out to be a pause rather than a bottom. A brand-new CEO adds execution uncertainty at the exact moment the thesis needs steady hands.

And one risk covers all five: fair value is not a floor. These stocks have already demonstrated, this year, that they can fall while their fundamentals improve. Nothing about a Fair Value tag prevents a second leg down in a broad market drawdown; it only changes what you are paying for the business when the leg arrives. The platform's scores say the current prices are reasonable for the current fundamentals. If the fundamentals crack, the scores will follow them down, and so will the fair values. That is not a flaw in the system. That is the system working.

The Bottom Line

The first half of 2026 repriced quality without, so far, breaking it. More than half of the platform's Elite and Strong universe lost ground in six months, and inside that group sit five companies whose declines came with growing earnings attached: a medtech leader marked down on drug fears its own patient data disputes, a market-infrastructure toll road marked down after the best quarter in its history, an elite underwriter marked down for decelerating from exceptional to merely excellent, a two-brand consumer compounder marked down over a margin guide, and a salvage-auction monopoly marked down on a volume slump that has already begun to narrow.

What the five have in common is where they landed: at or near the platform's calculated fair value, a place businesses of this quality rarely visit. We have been deliberate about the honest framing. The scores do not call these stocks cheap, and neither do we. The argument is narrower and, we think, stronger: the premiums are gone, the fundamentals are not, and the market is now offering proven businesses at prices that assume nothing good happens next.

That is the Wealth Engine Pro approach: run the screen, verify the data, throw out the artifacts, and say plainly what the numbers do and do not support. This edition inaugurates an annual tradition; the same screen runs every year on the first Friday of July, and we will grade the results when it does. In the meantime, look these five up on the platform, check the scores and fair values yourself, and decide whether a fair price for a strong business is opportunity enough. The data says the quality held. The price of admission just got reset.